Literature DB >> 2465444

Nonsteroidal antiinflammatory drugs aggravate acute myocardial ischemia in the perfused rabbit heart: a role for prostacyclin.

F Berti1, G Rossoni, F Magni, D Caruso, C Omini, L Puglisi, G Galli.   

Abstract

Myocardial ischemia was induced in perfused paced isovolumic left heart preparation of the rabbit by reducing, for a period of 40 min, the flow rate from 20 ml/min to 0.2 ml/min (severe model) and to 1 ml/min (moderate model). The relationship between prostaglandin biosynthesis and cardiac ischemic damage was evaluated in the two experimental models. The results obtained indicate that the total amount of 6-keto-PGF1 alpha generated increases with the severity of the ischemia, particularly during the 20 min of reperfusion (moderate model 81.8 +/- 13.7 ng: severe model 375 +/- 102 ng). The inhibition of the prostaglandin synthesis, prostaglandin-E2, and 6-keto-prostaglandin-F1 alpha (PGE2 and 6-keto-PGF1 alpha levels below the detection limits) by Aspirin (20 micrograms/ml) and Indomethacin (1 microgram/ml) in moderate myocardial ischemia was correlated with greater increments in resting diastolic tension (nearly 100% and 40%, respectively). This phenomenon was also associated to a further decrease on cardiac contractility and increase on coronary perfusion pressure upon reperfusion. On the contrary drugs which stimulated prostaglandin generation in myocardial tissue, such as Defibrotide (400 micrograms/ml), completely protected the organ from ischemia. U-60257 (3 micrograms/ml) and FPL-55712 (2 micrograms/ml), compounds, which respectively inhibits biosynthesis and the effects of leukotrienes, displayed a beneficial activity on this moderate model of ischemia. The present data suggests that the deleterious effect of nonsteroidal antiinflammatory drugs in low flow myocardial ischemia and reperfusion damage may be associated with removal of PGI2 and PGE2 from ischemic myocardium.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2465444     DOI: 10.1097/00005344-198810000-00009

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

1.  Inhibition of cyclo-oxygenase-2 exacerbates ischaemia-induced acute myocardial dysfunction in the rabbit.

Authors:  Giuseppe Rossoni; Marcelo N Muscara; Giuseppe Cirino; John L Wallace
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

Review 2.  Defibrotide: a review of its use in severe hepatic veno-occlusive disease following haematopoietic stem cell transplantation.

Authors:  Gillian M Keating
Journal:  Clin Drug Investig       Date:  2014-12       Impact factor: 2.859

3.  Formation of sulphidopeptide-leukotrienes by cell-cell interaction causes coronary vasoconstriction in isolated, cell-perfused heart of rabbit.

Authors:  A Sala; G Rossoni; C Buccellati; F Berti; G Folco; J Maclouf
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

4.  Defibrotide reduces infarct size in a rabbit model of experimental myocardial ischaemia and reperfusion.

Authors:  C Thiemermann; G R Thomas; J R Vane
Journal:  Br J Pharmacol       Date:  1989-06       Impact factor: 8.739

Review 5.  Cardiovascular risks and benefits of perioperative nonsteroidal anti-inflammatory drug treatment.

Authors:  F Camu; C Van Lersberghe; M H Lauwers
Journal:  Drugs       Date:  1992       Impact factor: 9.546

6.  The hydrogen sulphide-releasing derivative of diclofenac protects against ischaemia-reperfusion injury in the isolated rabbit heart.

Authors:  G Rossoni; A Sparatore; V Tazzari; B Manfredi; P Del Soldato; F Berti
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

7.  Defibrotide versus heparin in the prevention of coronary reocclusion after thrombolysis in acute myocardial infarction.

Authors:  M Tubaro; G Mattioli; F Matta; C Cappello; E Natale; R Ricci; P Gerardi; F Milazzotto
Journal:  Cardiovasc Drugs Ther       Date:  1993-11       Impact factor: 3.727

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.